Development of proprietary bacteriophage Qbeta as a vaccine carrier platform for anti-salmonella vaccine

开发专有噬菌体Qbeta作为抗沙门氏菌疫苗的疫苗载体平台

• 批准号: 10448433
• 负责人: Herbert Wanjala Kavunja
• 金额: $ 29.46万
• 依托单位: IASO THERAPEUTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-07-09 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10448433
• 关键词: Address; Antibodies; Antibody Response; Antigen Targeting; Antigens; Bacteriophages; Benchmarking; Biotechnology; COVID-19 pandemic; Carbohydrates; Cell surface; Centers for Disease Control and Prevention (U.S.); Cessation of life; Characteristics; Chemosensitization; Clinical; Clinical Data; Clinical Research; Communicable Diseases; Conjugate Vaccines; Development; Disease; Drug resistance; Epitopes; Escherichia coli EHEC; Escherichia coli O157; Food Poisoning; Future; Genetic Engineering; Health; Helper-Inducer T-Lymphocyte; Human; Immune; Immune response; Immune system; Immunize; Immunoglobulin G; Incidence; Infection; Intellectual Property; Licensing; Malignant Neoplasms; Mediation; Michigan; Multi-Drug Resistance; Mus; Pain; Pathogenicity; Pathologic; Phase; Polysaccharides; Process; Production; Protocols documentation; Reproducibility; Safety; Salmonella; Salmonella Vaccines; Salmonella infections; Salmonella paratyphi; Salmonella typhi; Salmonella typhimurium; Savings; Small Business Innovation Research Grant; Societies; System; T-Lymphocyte Epitopes; Technology; Therapeutic; Universities; Vaccine Antigen; Vaccine Design; Vaccines; Vertebral column; Virus-like particle; analytical method; base; biomaterial compatibility; cross reacting material 197; design; fighting; foodborne illness; head-to-head comparison; immunogenic; immunogenicity; mouse model; mutant; next generation; novel; novel vaccines; pre-clinical; protective efficacy; side effect; tool; vaccine access; vaccine candidate; vaccine development; vaccine efficacy; vaccine platform; vaccine safety

Project summary Vaccines have saved millions of lives. However, there are many diseases against which vaccines are not yet available, with the current COVID-19 pandemic in the world serving as a painful reminder of the need for vaccines against emerging diseases. With the growing emphasis on vaccine safety, next-generation vaccine designs have been increasingly focusing on subunit antigens. Because subunit epitopes tend to have lower immunogenicity, immunogenic carriers are critical to deliver the desired antigen to the immune system and to enhance the immune responses. However, there are very few carriers available that have been validated in clinical studies. In this SBIR phase I project, Iaso Therapeutics, Inc. will focus on the development of a proprietary bacteriophage mutant Qβ (mQβ) virus like particle as a platform technology for conjugate vaccines. In aim 1, robust protocols will be established for expression, purification, and long-term storage of mQβ. In addition, head to head comparison will be performed to demonstrate that mQβ can elicit higher levels of antibodies as compared to current benchmark carriers. In aim 2, the powerful mQβ platform will be applied to deliver Salmonella associated glycans as potential vaccines against multiple strains of common pathogenic Salmonella. The vaccine will be optimized to enhance protection from Salmonella infection. When successfully developed, this project will establish mQβ as an attractive immunogenic carrier for vaccine development and provide important pre-clinical data for anti-Salmonella vaccines.

项目摘要 疫苗挽救了数百万人的生命。然而，有许多疾病是疫苗不能预防的。 然而，目前世界上的COVID-19大流行痛苦地提醒人们， 针对新出现疾病的疫苗。随着对疫苗安全性的日益重视，下一代疫苗 设计越来越集中于亚单位抗原。因为亚单位表位往往具有较低的 免疫原性、免疫原性载体对于将所需抗原递送至免疫系统和 增强免疫反应。然而，只有很少的载体已经过验证， 临床研究。在该SBIR I期项目中，Iaso Therapeutics，Inc.将专注于开发一种专有的 噬菌体突变体Qβ（mQβ）病毒样颗粒作为结合疫苗的平台技术。在目标1中， 将为mQβ的表达、纯化和长期储存建立稳健的方案。此外，头 将进行头端比较，以证明mQβ可以引发更高水平的抗体， 到目前的基准运营商。在目标2中，强大的mQβ平台将用于递送沙门氏菌 相关聚糖作为针对多种常见致病性沙门氏菌菌株的潜在疫苗。的 将优化疫苗以增强对沙门氏菌感染的保护。如果成功开发， 该项目将确定mQβ作为疫苗开发的有吸引力的免疫原性载体，并提供重要的 抗沙门氏菌疫苗的临床前数据。